Skip to main content

Advertisement

Table 3 Drug exposure and duration of illness

From: Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease

  Treatment initiated
Duration of symptoms at the NPV Before NPV 1-2 years after NPV 3 years after NPV Never treated Total
<2 years 37 (5.8) 49 (7.6) 5 (0.8) 18 (2.8) 109 (17.0)
2-3 years 98 (15.3) 112 (17.5) 10 (1.6) 33 (5.1) 253 (39.5)
4-5 years 79 (12.3) 80 (12.5) 2 (0.3) 13 (2.0) 174 (27.1)
≥6 years 59 (9.2) 34 (5.3) 1 (0.2) 11 (1.7) 105 (16.4)
Total 273 (42.6) 275 (42.9) 18 (2.8) 75 (11.7) 641 (100.0)
  1. Values are presented as number (percentage). NPV, new patient visit.